

7th Annual MarketsandMarkets High Potent Medicines Conference - Challenges in Development & Deployment

2-day event discussing trends, challenges & disruptions within the HPAPI Industry.

PUNE, MH , INDIA, May 16, 2022
[/EINPresswire.com/](https://EINPresswire.com/) --

HPAPI's or Highly Potent Active Pharmaceutical Ingredients are a niche of pharma compounds which bring about a biological response at a very low dosage. With cancer research ramping up due to technological innovations, the subsequent growth of HPAPI's is evident. Allowing for great management & recovery from cancers, tumors and other chronic illnesses, highly potent medicines are being preferred & are in demand as they allow for great results with minimal exposure to medication for patients.



Having said that, several factors create hinderances within the drug development life cycle of highly potent medicines. Discrepancies in accurate classification of HPAPI's into appropriate occupational exposure band (OEB), huge investments into state-of-the-art laboratories, high risk of cross contamination & extremely tricky and fragile handling requirements are few which spring to mind.

The 7th ANNUAL MARKETSandMARKETS HIGH POTENT MEDICINES CONFERENCE scheduled from 25th-26th MAY 2022 in LONDON, UK aims to explore groundbreaking advances, future applications, regulatory developments, upcoming challenges & the roadmap for future growth of the HPAPI industry.

KEY HIGHLIGHTS & EXPECTED TAKEAWAYS:

- oProcess Development and scaling up of HPAPI's.
- oStrategies for effective outsourcing partnerships.
- oTraining sessions on handling of complex high potent compounds & discussion on containment strategies for HPAPI's.
- oValidation of cleaning procedures to avoid cross contamination.
- oRegulatory Landscape - Understanding the updated regulatory guidelines in the HPAPI

lifecycle.

o Hazard Assessment Classifications

A GLIMPSE AT THE ESTEEMED SPEAKER PANEL:

o Babio Zenobi, EHS Director, BSP Pharmaceuticals - Italy

o Stefano Butti, Sales Director, Food Pharma Systems (FPS) - Italy

o Thomas Adam, Head of Global Quality Assurance Chemical APIs, Bayer – Germany

o David O'Connell, Director, Scientific Affairs, PCI Pharma Services – UK

o Martin Axon, Senior Principal, Occupational Hygienist, SafeBridge – Europe

o William Hawkins, Managing Toxicologist, SafeBridge – Europe

o Richard Arnette, Manager, Industrial Hygiene and Toxicology, Pharmascience – Canada

o Kenneth Farrugia, Operations Manager, MINT Health – Malta

o Red Ohsiek, Senior Validation Manager, Ecolab – USA

[FIND OUT MORE. EXPLORE THE ENTIRE 2-DAY AGENDA HERE!](#)

[REGISTER FOR THE CONFERENCE!](#)

Ayush Kanitkar

MarketsandMarkets

+91 8975985061

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/572633810>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.